09995.HK
RemeGen Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 80.00
−1.48%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
6.6x
Market Cap
HKD 44.75B
MomentumView details →
1D Return
−1.48%
YTD Return
+11.11%
RSI (14)
48.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
6.6x
Market Cap
HKD 44.75B
RSI (14)
48.6
MomentumView details →
1D Return
−1.48%
YTD Return
+11.11%
Similar companies
Latest newsMore news →
China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.4d agoRemeGen Co., Ltd. announced its 2026 interim results, reporting a net profit of 4.662 billion yuan, turning from a loss in the prior year.11d agoRemeGen forecast first-half 2026 revenue of 5.85 billion yuan.17d ago